Fixed ratio drug combination treatments for solid tumors
AssigneeCelator Pharmaceuticals, Inc.
InventorsAndrew Janoff, Lawrence Mayer, John Redman, Christine Swenson
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors.
Claims7
A method to treat an advanced solid cancer in a human subject, said method comprising administering to said subject a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine, wherein said fixed, non-antagonistic molar ratio is maintained in the plasma for at least about 4 hours,
- wherein said fixed, non-antagonistic molar ratio of irinotecan and floxuridine is about 1:1 and is encapsulated in liposomes,
- wherein each dose of the composition is administered intravenously to said human subject over a period of 30 minutes to three hours, wherein the dose contains less than 0.0004 moles/m2 of floxuridine, and wherein floxuridine is administered at a level not greater than 0.0008 moles/m2/month, and
- wherein said advanced solid cancer is a gastric cancer, a renal cancer, a breast cancer, a colon cancer, an esophageal cancer, a prostate cancer, a pancreatic cancer, an ovarian cancer, an osteosarcoma, or a sphenoid sinus cancer.
Dependencies are inferred from the claim text.